Number of posts : 5798
Birthday : 1952-04-20
Age : 67
Reputation : 0
Points : 21611
Registration date : 2007-04-25
|Subject: Cyprotex Astra Zeneca, Baker Tilly, Novartis Vaccines, TRUSTECH, UL EduNeering, Waters Corporation, DWF LLP, Pinsent Masons LLP and MIMIT. Sun Aug 11, 2019 10:54 pm|| |
[size=1312/04/2013 | 07:06am EDT
Cyprotex awarded 2013 Biomedical Service Company of the Year
4th December 2013
Cyprotex PLC, the specialist ADME-Tox contract research organisation, has been awarded 'Biomedical Service Provider of the Year' at the prestigious Bionow Annual Awards Dinner on the 28th November 2013. The event was attended by over 300 executives from across the biomedical industry and it showcased the very best of this world class biomedical sector. The judging panel included representatives from Astra Zeneca, Baker Tilly, Novartis Vaccines, TRUSTECH, UL EduNeering, Waters Corporation, DWF LLP, Pinsent Masons LLP and MIMIT.
The decision was based on Cyprotex's strong application which highlighted the strong growth in the company (in 2012, revenues up 22.3% in 2012, robust EDITDA of £0.7 million, an operating profit of £0.32 million and 78 new customers) as well as significant ongoing contracts with Pfizer and the US EPA, and development of several cutting edge technologies such as eCiphrCardio and eCiphrNeuro in 2013.
Anthony Baxter PhD, chief executive of Cyprotex, comments: "We are delighted to have won the prestigious Bionow Biomedical Service Company of the Year award. Our dedicated team at our facilities in the UK and the US has made this possible and they have worked hard to achieve where we are today. Investment of £7 million in the company by Harwood Capital as announced in August this year has facilitated expansion into a laboratory at the Alderley Park's Biohub site as well as a high throughput laboratory over at our Watertown site - to be launched in the New Year. We are looking forward to further growth and expansion during 2014."